Skip to content
Open access

Cognitive and Biomarker Signatures of Late-Onset Temporal Lobe Epilepsy

Aug 2026 · Neurology · Vol 107, pp. e218464 - e218464 · 0 citations · 51 references
Medicine

TL;DR

Cognitive and CSF phenotype of LO-TLE with normal CSF AD biomarkers is characterized by distinct cognitive and biological features compared with MCI-AD, suggesting a disease process independent of AD.

Abstract

Background and Objectives Late-onset unexplained epilepsy (LOUE) represents a substantial proportion of epilepsies with onset after 50 years and often manifests as temporal lobe epilepsy (LO-TLE). Although a link with Alzheimer disease (AD) has been suggested, only a subset of LO-TLE shows AD-related biomarkers, indicating biological heterogeneity. This study aims to characterize the cognitive and CSF phenotype of LO-TLE and compare it with healthy controls (HCs) and patients with mild cognitive impairment due to AD (MCI-AD). Methods This Italian cross-sectional cohort study included LO-TLE patients with normal CSF β-amyloid (Aβ) biomarkers, MCI-AD, and age-matched and sex-matched HC. Participants underwent structural MRI, neuropsychological assessment, and CSF biomarkers assay, including neurofilament light chain (NfL) and the phosphorylated-to-total tau ratio (p/t-tau). Cortical thickness and subcortical volumes were quantified from structural MRI. Cognitive performance was summarized using principal component analyses. Group differences in imaging, cognition, and CSF biomarkers were assessed, and associations between CSF markers and cognition were examined within groups. Results The study included 18 LO-TLE, 24 MCI-AD, and 17 HC. LO-TLE showed preserved cortical thickness and subcortical volumes comparable with HC, whereas MCI-AD exhibited widespread cortical thinning and medial temporal atrophy. Despite normal imaging, LO-TLE showed lower performance compared with HC in episodic memory (t(53) = −7.79, pFDR < 0.001), short-term memory (t(53) = −2.94, pFDR = 0.007), language (t(53) = 4.12, pFDR < 0.001), and executive functions (t(53) = −3.76, pFDR < 0.001), while attention was preserved. Global cognitive performance further distinguished LO-TLE from MCI-AD, with the former group performing better (t(53) = 4.21, pFDR < 0.001). LO-TLE CSF profiles were characterized by low NfL levels and a p/t-tau ratio below the proposed cutoff of 0.17, whereas MCI-AD showed pathologic Aβ and tau alterations, elevated NfL, and p/t-tau ratio above 0.17. In LO-TLE, a higher p/t-tau ratio was associated with better performance on global cognition (rs = 0.585, pFDR = 0.032) and short-term memory (rs = 0.588, pFDR = 0.032), whereas no associations emerged in MCI-AD. Discussion LO-TLE with normal CSF AD biomarkers is characterized by distinct cognitive and biological features compared with MCI-AD, suggesting a disease process independent of AD. The low p/t-tau ratio may reflect alternative pathophysiologic mechanisms and warrants further investigation in larger longitudinal studies to clarify the underlying pathology and clinical trajectories.

Read PDF

Similar papers

Open access Jul 2026

Structural Brain Biomarkers for Identifying Progressive Amnestic Mild Cognitive Impairment

The study revealed structural brain abnormalities in aMCI, characterized by reduced hippocampal and hippocampal subfield volumes, as well as amygdala volume reduction, while other subcortical structures were relatively preserved.

N. Cherkasov, A. Tomyshev, E. Abdullina et al. · 0 citations
Open access Aug 2026

Instrumental, Neurophysiological, cognitive and Sleep InvestiGations into the High risk of neurodegeneraTion in Late Onset Epilepsy of Unknown aetiology: the INSIGHT-LOEU study.

This strategy could improve the early detection of cognitive decline, guide personalised management, and ultimately enhance quality of life, while contributing to the long-term sustainability of healthcare systems in an ageing population, focusing on LOEU as a model for dementia prevention.

G. Bergamo, M. Fernandes, S. Maio et al. · 0 citations
Open access Aug 2026

EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease

Findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification and support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.

T. Paranhos, Yuta Katsumi, M. Brickhouse et al. · 0 citations
Open access Sep 2026

HIPPOCAMPAL TAU-RELATED SIGNAL INDEXES HYPEREXCITABILITY AND NREM SLEEP–MEMORY DYSFUNCTION IN TEMPORAL LOBE EPILEPSY

It is suggested that hippocampal 18F-MK6240 uptake may represent a candidate marker of circuit vulnerability associated with NREM sleep-memory dysfunction in TLE, warranting validation in larger longitudinal studies.

Thaera Arafat, Katharina Schiller, J. Lam et al. · 0 citations
Review Sep 2026

Atypical Alzheimer disease: a multi-axis framework toward defining heterogeneity.

A practical multi-axis framework comprising clinical phenotype, AD biological context (AD pathology plus co-pathologies and molecular modifiers), network topography (regional patterns) and tempo (rate of clinical and biomarker progression) is proposed to reduce diagnostic mismatches, make cohorts more comparable and su...

L. Grinberg, M. Murray · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.